MLYCD

Across TCGA pan-cancer cohorts, MLYCD mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MLYCD data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MLYCD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MLYCD expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where MLYCD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.865	1.000	.002	13	view →
HNSC	DFS	Quartile	All	0.903	1.000	.015	10	view →
LSCC	OS	Median	All	0.811	0.930	.021	7	view →
PDAC	DFS	Median	II,III,IV	0.874	0.678	.009	6	view →
UCEC	DFS	Tertile	All	0.924	1.000	.041	2	view →
GBM	DFS	Quartile	All	0.491	0.328	.033	2	view →
LUAD	OS	Tertile	III,IV	0.867	0.442	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MLYCD–CCRCC (DFS)

Open the CCRCC breakdown →